V.I. Technologies
This article was originally published in The Gray Sheet
Executive Summary
Health Care Financing Administration assigns a HCPCS product code and reimbursement rate for the company's PLAS+SD transfusion plasma product. The system utilizes a solvent detergent process to inactivate deadly viruses such as HIV, hepatitis C and hepatitis B in plasma. Effective July 1, the rate has been set at $169, representing a $60 premium over the reimbursement rate for untreated fresh frozen plasma. According to the company, approximately 50-60% of procedures are done on Medicare patients and sales are expected to benefit from the new code
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.